drugset / Trial / NCT05302024
Efficacy and Safety of Iguratimod in the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia
NaSingle-groupOpen-labelTreatment
Summary
A phase 2, open-label, single-arm study to evaluate the efficacy and safety of iguratimod for the treatment of adults with steroid-resistant/relapse immune thrombocytopenia (ITP)
Timeline
- Start
- 2022-03-22
- Primary completion
- 2023-12-12
- Completion
- 2023-12-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Iguratimod | Small molecule | 25 mg | Oral |